$198 Million is the total value of Prosight Management, LP's 39 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 61.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZBH | Buy | ZIMMER BIOMET HLDGS INC | $19,382,000 | +22.9% | 164,619 | +33.3% | 9.77% | +41.6% |
| BMY | Buy | BRISTOL MYERS SQUIBB CO | $18,616,000 | +37.9% | 410,490 | +45.0% | 9.39% | +58.9% |
| KURA | Buy | KURA ONCOLOGY INC | $17,087,000 | +495.8% | 867,810 | +401.9% | 8.62% | +586.5% |
| URGN | Buy | UROGEN PHARMA LTD | $9,378,000 | +60.8% | 260,928 | +65.3% | 4.73% | +85.3% |
| QURE | New | UNIQURE NV | $9,378,000 | – | 120,000 | +100.0% | 4.73% | – |
| SBBP | Buy | STRONGBRIDGE BIOPHARMA PLC | $7,972,000 | +71.4% | 2,546,997 | +172.7% | 4.02% | +97.5% |
| FIXX | New | HOMOLOGY MEDICINES INC | $7,222,000 | – | 369,048 | +100.0% | 3.64% | – |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $6,692,000 | +8.1% | 450,000 | +80.4% | 3.37% | +24.6% |
| CNC | Buy | CENTENE CORP DEL | $6,634,000 | +59.4% | 126,500 | +61.4% | 3.34% | +83.7% |
| ALDX | Buy | ALDEYRA THERAPEUTICS INC | $4,188,000 | -20.5% | 697,921 | +19.7% | 2.11% | -8.3% |
| CBIO | Buy | CATALYST BIOSCIENCES INC | $4,032,000 | +2.7% | 547,092 | +13.0% | 2.03% | +18.3% |
| Buy | INTEC PHARMA LTD JERUSALEM | $3,541,000 | -11.0% | 815,789 | +50.3% | 1.78% | +2.5% | |
| EOLS | New | EVOLUS INC | $1,646,000 | – | 112,590 | +100.0% | 0.83% | – |
| PSNL | New | PERSONALIS INC | $1,533,000 | – | 56,446 | +100.0% | 0.77% | – |
| SRRA | Buy | SIERRA ONCOLOGY INC | $1,502,000 | -64.3% | 2,681,618 | +9.1% | 0.76% | -58.8% |
| UROV | Buy | UROVANT SCIENCES LTD | $1,128,000 | +12.4% | 142,620 | +42.8% | 0.57% | +29.6% |
| ARQL | New | ARQULE INC | $921,000 | – | 83,675 | +100.0% | 0.46% | – |
| ADMA | New | ADMA BIOLOGICS INC | $719,000 | – | 185,721 | +100.0% | 0.36% | – |
| UTHR | New | UNITED THERAPEUTICS CORP DEL | $671,000 | – | 8,600 | +100.0% | 0.34% | – |
| CDTX | Buy | CIDARA THERAPEUTICS INC | $603,000 | +3.3% | 358,963 | +63.0% | 0.30% | +18.8% |
| KZR | New | KEZAR LIFE SCIENCES INC | $264,000 | – | 34,224 | +100.0% | 0.13% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.